Shire’s binge-eating push on Vyvanse feeds Q1 earnings beat

Carly Helfand

When  in February won the FDA's first-ever approval for binge eating disorder (BED), Shire predicted the indication could help the med rake in an extra $ 200 million to $ 300 million. Shire is already making its way there, it said Thursday, and the new sales helped the company notch a Q1 profit .

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS